Today GILD releaseed a statement on remdesivir, saying data is INCONCLUSIVE, no statistical power to determine efficacy, and reports are anecdotal - after its stocks surged after hours.
Gilead issued a statement which suggested that STAT was pumping the stock based on nothing more than "anecdotal reports" to wit:
"We understand the urgent need for a Covid-19 treatment and the resulting interest in data on our investigational antiviral drug remdesivir. The totality of the data need to be analysed in order to draw any conclusions from the trial."
"Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for Covid-19. We expect the data from our Phase 3 study in patients with severe Covid-19 infection to be available at the end of this month, and additional data from other studies to become available in May."
https://www.barrons.com/articles/stock-futures-soar-on-gilead-coronavirus-drug-report-51587079853
Submitted April 16, 2020 at 10:41PM by postopenheartsurgery https://ift.tt/3bg28gF
